TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03385044

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MOVT
Description: ETT cuff will be inflated till the disappearance of audible air leak on auscultation, while abdominal carbon dioxide (CO2) inflation is maintained with peak inspiratory pressure of 25 cm H2O during volume controlled ventilation. The patient will be in the Trendelenburg position.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VE/VI ratio of Spirometer
Description: ETT cuff will be inflated till the VE/VI ratio meets the initial VE/VI ratio, while abdominal CO2 inflation is maintained with peak inspiratory pressure of 25 cm H2O during volume controlled ventilation. The patient will be in the Trendelenburg position.
Study: NCT01803230

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02518724

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RIPC intervention exposure
Description: placing a sphygmomanometer on the non-dominant hand and applying pressure of 200 mmHg for 5 min followed by 5 min without pressure X 4 repeats

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placebo intervention exposure
Description: placing a sphygmomanometer on the non-dominant hand and applying pressure of 100 mmHg for 5 min followed by 5 min without pressure X 4 repeats.
Study: NCT00575068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDEC-114
Description: Phase 1-A Group 1 - 125 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-A Group 2 - 250 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-A Group 3 - 375 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-B Group 4 - 500 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase II-A \& II-B - Dosage start at the MTD (up to 375 mg/m2)
Study: NCT02237339

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Uric acid lowering medication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00240526

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™ -B
Description: 3 (Groups A and C) or 4 (Groups B and D) intramuscular injections during the primary study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™ -B
Description: 3 (Groups A and C) or 4 (Groups B and D) intramuscular injections during the primary study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™ -B
Description: 3 (Groups A and C) or 4 (Groups B and D) intramuscular injections during the primary study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™ -B
Description: 3 (Groups A and C) or 4 (Groups B and D) intramuscular injections during the primary study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B immunoglobulin (HBIg)
Description: 1 intramuscular injections at birth (primary study)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B immunoglobulin (HBIg)
Description: 1 intramuscular injections at birth (primary study)
Study: NCT01756560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethsone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Study: NCT01560260

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linsitinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT01837290

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine infusion for premedication
Description: Group Dexmedetomidine (Group D): Midazolam 0.02 mg/kg + 0.5 μg/kg/10 min dexmedetomidine infusion for premedication; Spinal block (Hyperbaric bupivacaine 0.5% 12.5 mg) (n=30)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: intravenous Midazolam 0.02 mg/kg for premedication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: intravenous Midazolam 0.02 mg/kg for premedication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline infusion
Description: Saline infusion to facilitate blinding

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Spinal block with hyperbaric bupivacaine 0.5% 12.5 mg
Description: Hyperbaric bupivacaine injection for spinal block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinal block with hyperbaric bupivacaine 0.5% 12.5 mg
Description: Hyperbaric bupivacaine injection for spinal block
Study: NCT04353193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: Terlipressin 1mg IV bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: Terlipressin by IV continuous infusion at a rate of 2mg/day (max 4mg/day) during 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: Octreotide 50mcg IV bolus plus continuous infusion at a rate of 50mcg/h during 2 hours
Study: NCT02223117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thrombosomes
Description: Freeze-dried platelets

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00125593

Intervention type: DRUG
Group type: OTHER
Intervention: Simvastatin 20 mg
Description: Once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 20 mg
Description: Once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe 10mg
Description: Once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily
Study: NCT02777996

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Computed Tomography
Description: Assessment protocol were adopted from the ELCAP study (modified) for Non Calcific Nodule with a diameter of less- equal than 5 mm at baseline and 3mm at repeated.
Study: NCT02035813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib/Everolimus in combination with endocrine therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Study: NCT01743690

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Probiotic lactobacilli reuteri

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Probiotic lactobacilli reuteri

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nystatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nystatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluocinolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluocinolone
Study: NCT03590665

Intervention type: OTHER
Group type: OTHER
Intervention: Hand grip exercise and lower body negative pressure
Description: For participants with Down syndrome, the first visit includes baseline measures and familiarization with the graded maximal exercise test protocol. If necessary, additional familiarization sessions will be scheduled for people with Down syndrome. The second visit, we perform the graded maximal exercise test and familiarize the participant with the procedures for the third visit: the hand grip exercise protocol and the lower body negative pressure (LBNP) box. The third visit we assess the peripheral blood flow during the hand grip exercise protocol without and with the LBNP. For control subjects, the first and second visit are combined. Their second visit is the same as the third visit for individuals with Down syndrome.

Intervention type: OTHER
Group type: OTHER
Intervention: Hand grip exercise and lower body negative pressure
Description: For participants with Down syndrome, the first visit includes baseline measures and familiarization with the graded maximal exercise test protocol. If necessary, additional familiarization sessions will be scheduled for people with Down syndrome. The second visit, we perform the graded maximal exercise test and familiarize the participant with the procedures for the third visit: the hand grip exercise protocol and the lower body negative pressure (LBNP) box. The third visit we assess the peripheral blood flow during the hand grip exercise protocol without and with the LBNP. For control subjects, the first and second visit are combined. Their second visit is the same as the third visit for individuals with Down syndrome.
Study: NCT01953770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-L-asparaginase ind
Description: 1,000 U/m2 on day 3 of induction therapy, intravenously, in 200 ml of saline, during 1 hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-L-asparaginase ind
Description: 1,000 U/m2 on day 3 of induction therapy, intravenously, in 200 ml of saline, during 1 hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-L-asparaginase cons
Description: 1,000 U/m2 intravenously, in 200 ml of saline, during 1 hour, 24 hours after methotrexate on weeks 7, 9, and 11 - days 44, 58, and 72 (phase S1), weeks 15, 17, and 19 - days 100, 114, 128 (phase S2), weeks 23, 25, and 27 - days 156, 170, 184 (phase S3).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E.coli L-asparaginase
Description: E.coli L-asparaginase (asparaginase medac) 5,000 U/m2 intramuscularly weekly, 24 hours after methotrexate dose, from week 7 to week 12 - days 44, 51, 58. 65, 72, 79 (phase S1), from week 15 to week 20 - days 100, 107, 114, 121, 128, 135 (phase S2), from week 23 to week 28 - days 156, 163, 170, 177, 184, 191 (phase S3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose Methotrexate
Description: 2,000 mg/m2 per 24 hours is given at days 43, 57, and 71 (weeks 7, 9, and 11). 1/5 of the total dose is given as slow intravenous bolus over 3-5 minutes. 4/5 of the total dose of methotrexate is injected as continuous 24 hours infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose Methotrexate
Description: 30 mg/м2 is given intramuscularly 1 time weekly - days 43, 50, 57, 64, 71, and 78 (weeks 7, 8, 9, 10, 11, and 12).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple intrathecal therapy
Description: Intrathecal injection of 3 drugs is additionally given three times during phase S-2 (weeks 15, 17, and 19 - days 99, 113, and 127), and three times during phase S-3 (weeks 23, 25, and 27 - days 155, 169, and 183).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Cranial irradiation
Description: 12 Gy cranial irradiation is conducted at weeks 31-32 of the Protocol in patients \>3 years of age

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Daunorubicin at a dose of 45 mg/m2 i.v. for 6 hours on day 8 of induction therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Description: Daunorubicin at a dose of 45 mg/m2 i.v. for 6 hours on day 8 of induction therapy
Study: NCT00406419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate tablet was administered orally at a dose 7.5-25 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate tablet was administered orally at a dose 7.5-25 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate tablet was administered orally at a dose 7.5-25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ocrelizumab
Description: Ocrelizumab was administered via IV infusion at a dose specified in arm description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ocrelizumab
Description: Ocrelizumab was administered via IV infusion at a dose specified in arm description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to ocrelizumab was administered via IV infusion
Study: NCT02104635

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delivery of a Post-Partum Package

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delivery of a Post-Partum Package
Study: NCT03632434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: tDCS generates a small electric current which modulates how easy it is for active brain cells to discharge. The device is a neoprene cap worn over the head, and in the cap there are two electrodes, which are small metal discs, where the current comes from.
Study: NCT01937637

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Intervention for Breathlessness
Description: Cognitive behavioral intervention for breathlessness, delivered by nurse practitioners during outpatient oncology appointments, in up to 8 patients with advanced lung cancer.
Study: NCT02678689

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMN190 recombinant human tripeptidyl peptidase-1 (rhTPP1)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraventricular access device
Description: Surgical implantation of an MRI compatible ICV access device in the lateral ventricle of the right hemisphere is required for administration of study drug.
Study: NCT00098254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 43-9006 (Sorafenib)
Description: Self administered oral doses at 400 mg twice a day with 250 ml (8 oz.) of water each morning and evening (i.e., 12-hourly) continuously in a 28 day cycle. Tablets may be taken with or without food.
Study: NCT01863927

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Research intervention
Description: After heat acclimation the participant will be randomly exposed to 4 conditions during four separate consecutive days: 1) walking on a treadmill for two hours in hot-wet conditions (30OC, 70% RH) while wearing military uniforms and a vest (control group); 2) walking on a treadmill for two hours in hot-dry conditions (40OC, 30% RH) while wearing military uniforms and a vest (control group); 3) walking on a treadmill for two hours in hot-wet conditions (30OC, 70% RH) while wearing military uniforms and a vest with a ventilator (experimental group); 4) walking on a treadmill for two hours in hot-dry conditions (40OC, 30% RH) while wearing military uniforms and a vest with a ventilator (experimental group)
Study: NCT02892682

Intervention type: OTHER
Group type: OTHER
Intervention: BLOOD TEST

Intervention type: OTHER
Group type: OTHER
Intervention: BLOOD TEST

Intervention type: OTHER
Group type: OTHER
Intervention: BLOOD TEST

Intervention type: OTHER
Group type: OTHER
Intervention: BLOOD TEST
Study: NCT05053048

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SL-PLUS-Stem for total hip arthroplasty
Description: Patients undergoing primary total hip arthroplasty are randomly assigned (1:1) to receive either an uncemented NT-SL-PLUS Stem (Smith\&Nephew Orthopaedics AG, Aarau, Switzerland) or a matching uncemented STD-SL-PLUS stem (Smith\&Nephew Orthopaedics AG, Aarau, Switzerland) in a blinded fashion.
Study: NCT01083940

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized reminders on hypertension intensification
Description: Reminder generated to prompt providers to intensify therapy when patient's blood pressure remains uncontrolled
Study: NCT01913639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study: NCT04361032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab Injection
Description: Tocilizumab (LOC) (8mg/ kg per day) (1 injection per infusion). Only on the 1st day (D0)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferoxamine
Description: Deferoxamine (Desferal 500 mg, powder, and solvent for IV solution for injection)
Study: NCT02385578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: an educational intervention
Description: the first step of the train the trainer plan(TTT) ,which including the diagnosis and operation hand in hand teach by Professor Yano Takeshiin,and the case discussion,and so on
Study: NCT01391351

Intervention type: OTHER
Group type: OTHER
Intervention: blood samples
Description: blood samples in patients receiving Taxol and carboplatin chemotherapy :~* On Day 1 of the first course of chemotherapy~* On Day 1 of the second course of chemotherapy~* Before the surgery, if programmed via J1 or the fourth cycle of chemotherapy~* At the end of chemotherapy

Intervention type: OTHER
Group type: OTHER
Intervention: blood samples
Description: blood samples in patients receiving Taxol and carboplatin chemotherapy with avastin:~* On Day 1 of the first course of chemotherapy~* On Day 1 of the second course of chemotherapy~* Before the surgery, if programmed via J1 or the fourth cycle of chemotherapy~* At the end of chemotherapy
Study: NCT04261179

Intervention type: DRUG
Group type: OTHER
Intervention: Lymphoseek
Description: 50 μg microgram(s), timepoint: 30-60 minutes

Intervention type: DRUG
Group type: OTHER
Intervention: Nanocoll
Description: 500 μg microgram(s), timepoint: 30-60 minutes
Study: NCT02872727

Intervention type: OTHER
Intervention: Respiratoy health, biological investigations
Description: Once the subjects have agreed to participate, self-surveys on their lifestyle habits will be filled and EACand urine samplings will be taken during one same consultation, in addition to exhaled CO and No measurements. This consultation will also include a spirometry test. The employees' workstation data (and their evolution since the first study) will be collected. Therefore, the volunteers' participation is limited to one single visit including non-invasive examinations and self-surveys.
Study: NCT00373932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coached exercise persistence intervention
Description: Collaborative symptom and exercise monitoring and weekly reinforcement for exercise persistence from nurse coach via a mobile device and telephone.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Monitored exercise persistence intervention
Description: Self-monitoring of symptoms and exercise using a mobile device
Study: NCT00924469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Abiraterone acetate tablets will be administered orally at a total dose of 1000 milligram (mg) per day at least 1 hour before a meal or 2 hours after a meal for 24 weeks in Group 1 and from Week 13 to Week 24 for Group 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone
Description: Abiraterone acetate tablets will be administered orally at a total dose of 1000 milligram (mg) per day at least 1 hour before a meal or 2 hours after a meal for 24 weeks in Group 1 and from Week 13 to Week 24 for Group 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: Leuprolide acetate will be administered at a dose of 22.5 mg (dose adjusted as per Investigator's discretion) as intramuscular injection (injection of a substance into a muscle) once every 12 weeks in Group 1 and Group 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide
Description: Leuprolide acetate will be administered at a dose of 22.5 mg (dose adjusted as per Investigator's discretion) as intramuscular injection (injection of a substance into a muscle) once every 12 weeks in Group 1 and Group 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone tablets will be administered orally as 5 mg once daily for 24 weeks in Group 1 and from Week 13 to Week 24 for Group 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone tablets will be administered orally as 5 mg once daily for 24 weeks in Group 1 and from Week 13 to Week 24 for Group 2.
Study: NCT02433548

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascia iliaca block
Description: injection of 30 mLs below the fascia iliaca

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: subcutaneous of 5 cc of normal saline
Study: NCT03648203

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology Enabled Asthma Management System
Description: See description of arm
Study: NCT04315415

Intervention type: DEVICE
Group type: OTHER
Intervention: Silk Voice
Description: Silk Voice comprised of silk protein and cross-linked hyaluronic acid (HA)

Intervention type: DEVICE
Group type: OTHER
Intervention: Silk Voice
Description: Silk Voice comprised of silk protein and cross-linked hyaluronic acid (HA)

Intervention type: DEVICE
Group type: OTHER
Intervention: Silk Voice
Description: Silk Voice comprised of silk protein and cross-linked hyaluronic acid (HA)
Study: NCT00630058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-424(H), PEG-IFN-a-2b, RBV
Description: MP-424 (three tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks
Study: NCT05053048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SL-PLUS-Stem for total hip arthroplasty
Description: Patients undergoing primary total hip arthroplasty are randomly assigned (1:1) to receive either an uncemented NT-SL-PLUS Stem (Smith\&Nephew Orthopaedics AG, Aarau, Switzerland) or a matching uncemented STD-SL-PLUS stem (Smith\&Nephew Orthopaedics AG, Aarau, Switzerland) in a blinded fashion.
Study: NCT03891472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patients will receive initial chemotherapy, followed by evaluation of the response to the treatment, followed by SBRT, followed by chemotherapy.
Description: mFOLFIRINOX \> SBRT \> mFOLFIRINOX \> Surgical Intervention
Study: NCT00630058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-424 (L), PEG-IFN-a-2b, RBV
Description: MP-424 (two tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks
Study: NCT01448954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADC3680B oral
Description: Once daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral
Description: Once daily for 28 days